Global Oncolytic Virus Therapy Market Analysis and Forecast 2024-2030
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
According to APO Research, The global Oncolytic Virus Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.
North America and Europe are the main markets, each accounting for about 40% of the market.
Report Includes
This report presents an overview of global market for Oncolytic Virus Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncolytic Virus Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncolytic Virus Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncolytic Virus Therapy revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Oncolytic Virus Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Oncolytic Virus Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics and Sorrento Therapeutics, etc.
Oncolytic Virus Therapy segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Oncolytic Virus Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncolytic Virus Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
According to APO Research, The global Oncolytic Virus Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.
North America and Europe are the main markets, each accounting for about 40% of the market.
Report Includes
This report presents an overview of global market for Oncolytic Virus Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncolytic Virus Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncolytic Virus Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncolytic Virus Therapy revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Oncolytic Virus Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Oncolytic Virus Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics and Sorrento Therapeutics, etc.
Oncolytic Virus Therapy segment by Company
- Amgen
- Oncolytics Biotech
- Viralytics
- Transgene SA
- Oncolys BioPharma
- Targovax
- PsiOxus Therapeutics
- SillaJen Biotherapeutics
- Sorrento Therapeutics
- Lokon Pharma
- Genelux Corporation
- Vyriad
- TILT Biotherapeutics
- Cold Genesys
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Vaccinia Virus-based Oncolytic Viruses
- Vesicular Stomatitis Virus-based Oncolytic Viruses
- Newcastle Disease Virus-based Oncolytic Viruses
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Oncolytic Virus Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncolytic Virus Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Oncolytic Virus Therapy Market by Type
1.2.1 Global Oncolytic Virus Therapy Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 HSV-based Oncolytic Viruses
1.2.3 Adenoviruses-based Oncolytic Viruses
1.2.4 Vaccinia Virus-based Oncolytic Viruses
1.2.5 Vesicular Stomatitis Virus-based Oncolytic Viruses
1.2.6 Newcastle Disease Virus-based Oncolytic Viruses
1.3 Oncolytic Virus Therapy Market by Application
1.3.1 Global Oncolytic Virus Therapy Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Melanoma
1.3.3 Prostate Cancer
1.3.4 Breast Cancer
1.3.5 Ovarian Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ONCOLYTIC VIRUS THERAPY MARKET DYNAMICS
2.1 Oncolytic Virus Therapy Industry Trends
2.2 Oncolytic Virus Therapy Industry Drivers
2.3 Oncolytic Virus Therapy Industry Opportunities and Challenges
2.4 Oncolytic Virus Therapy Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Oncolytic Virus Therapy Market Perspective (2019-2030)
3.2 Global Oncolytic Virus Therapy Growth Trends by Region
3.2.1 Global Oncolytic Virus Therapy Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Oncolytic Virus Therapy Market Size by Region (2019-2024)
3.2.3 Global Oncolytic Virus Therapy Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Oncolytic Virus Therapy Revenue by Players
4.1.1 Global Oncolytic Virus Therapy Revenue by Players (2019-2024)
4.1.2 Global Oncolytic Virus Therapy Revenue Market Share by Players (2019-2024)
4.1.3 Global Oncolytic Virus Therapy Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Oncolytic Virus Therapy Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Oncolytic Virus Therapy Key Players Headquarters & Area Served
4.4 Global Oncolytic Virus Therapy Players, Product Type & Application
4.5 Global Oncolytic Virus Therapy Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Oncolytic Virus Therapy Market CR5 and HHI
4.6.2 Global Top 5 and 10 Oncolytic Virus Therapy Players Market Share by Revenue in 2023
4.6.3 2023 Oncolytic Virus Therapy Tier 1, Tier 2, and Tier
5 ONCOLYTIC VIRUS THERAPY MARKET SIZE BY TYPE
5.1 Global Oncolytic Virus Therapy Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Oncolytic Virus Therapy Revenue by Type (2019-2030)
5.3 Global Oncolytic Virus Therapy Revenue Market Share by Type (2019-2030)
6 ONCOLYTIC VIRUS THERAPY MARKET SIZE BY APPLICATION
6.1 Global Oncolytic Virus Therapy Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Oncolytic Virus Therapy Revenue by Application (2019-2030)
6.3 Global Oncolytic Virus Therapy Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Comapny Information
7.1.2 Amgen Business Overview
7.1.3 Amgen Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
7.1.5 Amgen Recent Developments
7.2 Oncolytics Biotech
7.2.1 Oncolytics Biotech Comapny Information
7.2.2 Oncolytics Biotech Business Overview
7.2.3 Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
7.2.5 Oncolytics Biotech Recent Developments
7.3 Viralytics
7.3.1 Viralytics Comapny Information
7.3.2 Viralytics Business Overview
7.3.3 Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
7.3.5 Viralytics Recent Developments
7.4 Transgene SA
7.4.1 Transgene SA Comapny Information
7.4.2 Transgene SA Business Overview
7.4.3 Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
7.4.5 Transgene SA Recent Developments
7.5 Oncolys BioPharma
7.5.1 Oncolys BioPharma Comapny Information
7.5.2 Oncolys BioPharma Business Overview
7.5.3 Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
7.5.5 Oncolys BioPharma Recent Developments
7.6 Targovax
7.6.1 Targovax Comapny Information
7.6.2 Targovax Business Overview
7.6.3 Targovax Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
7.6.5 Targovax Recent Developments
7.7 PsiOxus Therapeutics
7.7.1 PsiOxus Therapeutics Comapny Information
7.7.2 PsiOxus Therapeutics Business Overview
7.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
7.7.5 PsiOxus Therapeutics Recent Developments
7.8 SillaJen Biotherapeutics
7.8.1 SillaJen Biotherapeutics Comapny Information
7.8.2 SillaJen Biotherapeutics Business Overview
7.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
7.8.5 SillaJen Biotherapeutics Recent Developments
7.9 Sorrento Therapeutics
7.9.1 Sorrento Therapeutics Comapny Information
7.9.2 Sorrento Therapeutics Business Overview
7.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
7.9.5 Sorrento Therapeutics Recent Developments
7.10 Lokon Pharma
7.10.1 Lokon Pharma Comapny Information
7.10.2 Lokon Pharma Business Overview
7.10.3 Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
7.10.5 Lokon Pharma Recent Developments
7.11 Genelux Corporation
7.11.1 Genelux Corporation Comapny Information
7.11.2 Genelux Corporation Business Overview
7.11.3 Genelux Corporation Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
7.11.5 Genelux Corporation Recent Developments
7.12 Vyriad
7.12.1 Vyriad Comapny Information
7.12.2 Vyriad Business Overview
7.12.3 Vyriad Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
7.12.5 Vyriad Recent Developments
7.13 TILT Biotherapeutics
7.13.1 TILT Biotherapeutics Comapny Information
7.13.2 TILT Biotherapeutics Business Overview
7.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
7.13.5 TILT Biotherapeutics Recent Developments
7.14 Cold Genesys
7.14.1 Cold Genesys Comapny Information
7.14.2 Cold Genesys Business Overview
7.14.3 Cold Genesys Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
7.14.5 Cold Genesys Recent Developments
8 NORTH AMERICA
8.1 North America Oncolytic Virus Therapy Revenue (2019-2030)
8.2 North America Oncolytic Virus Therapy Revenue by Type (2019-2030)
8.2.1 North America Oncolytic Virus Therapy Revenue by Type (2019-2024)
8.2.2 North America Oncolytic Virus Therapy Revenue by Type (2025-2030)
8.3 North America Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
8.4 North America Oncolytic Virus Therapy Revenue by Application (2019-2030)
8.4.1 North America Oncolytic Virus Therapy Revenue by Application (2019-2024)
8.4.2 North America Oncolytic Virus Therapy Revenue by Application (2025-2030)
8.5 North America Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
8.6 North America Oncolytic Virus Therapy Revenue by Country
8.6.1 North America Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Oncolytic Virus Therapy Revenue by Country (2019-2024)
8.6.3 North America Oncolytic Virus Therapy Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Oncolytic Virus Therapy Revenue (2019-2030)
9.2 Europe Oncolytic Virus Therapy Revenue by Type (2019-2030)
9.2.1 Europe Oncolytic Virus Therapy Revenue by Type (2019-2024)
9.2.2 Europe Oncolytic Virus Therapy Revenue by Type (2025-2030)
9.3 Europe Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
9.4 Europe Oncolytic Virus Therapy Revenue by Application (2019-2030)
9.4.1 Europe Oncolytic Virus Therapy Revenue by Application (2019-2024)
9.4.2 Europe Oncolytic Virus Therapy Revenue by Application (2025-2030)
9.5 Europe Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
9.6 Europe Oncolytic Virus Therapy Revenue by Country
9.6.1 Europe Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Oncolytic Virus Therapy Revenue by Country (2019-2024)
9.6.3 Europe Oncolytic Virus Therapy Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Oncolytic Virus Therapy Revenue (2019-2030)
10.2 China Oncolytic Virus Therapy Revenue by Type (2019-2030)
10.2.1 China Oncolytic Virus Therapy Revenue by Type (2019-2024)
10.2.2 China Oncolytic Virus Therapy Revenue by Type (2025-2030)
10.3 China Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
10.4 China Oncolytic Virus Therapy Revenue by Application (2019-2030)
10.4.1 China Oncolytic Virus Therapy Revenue by Application (2019-2024)
10.4.2 China Oncolytic Virus Therapy Revenue by Application (2025-2030)
10.5 China Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Oncolytic Virus Therapy Revenue (2019-2030)
11.2 Asia Oncolytic Virus Therapy Revenue by Type (2019-2030)
11.2.1 Asia Oncolytic Virus Therapy Revenue by Type (2019-2024)
11.2.2 Asia Oncolytic Virus Therapy Revenue by Type (2025-2030)
11.3 Asia Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
11.4 Asia Oncolytic Virus Therapy Revenue by Application (2019-2030)
11.4.1 Asia Oncolytic Virus Therapy Revenue by Application (2019-2024)
11.4.2 Asia Oncolytic Virus Therapy Revenue by Application (2025-2030)
11.5 Asia Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
11.6 Asia Oncolytic Virus Therapy Revenue by Country
11.6.1 Asia Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Oncolytic Virus Therapy Revenue by Country (2019-2024)
11.6.3 Asia Oncolytic Virus Therapy Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Oncolytic Virus Therapy Revenue (2019-2030)
12.2 MEALA Oncolytic Virus Therapy Revenue by Type (2019-2030)
12.2.1 MEALA Oncolytic Virus Therapy Revenue by Type (2019-2024)
12.2.2 MEALA Oncolytic Virus Therapy Revenue by Type (2025-2030)
12.3 MEALA Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
12.4 MEALA Oncolytic Virus Therapy Revenue by Application (2019-2030)
12.4.1 MEALA Oncolytic Virus Therapy Revenue by Application (2019-2024)
12.4.2 MEALA Oncolytic Virus Therapy Revenue by Application (2025-2030)
12.5 MEALA Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
12.6 MEALA Oncolytic Virus Therapy Revenue by Country
12.6.1 MEALA Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Oncolytic Virus Therapy Revenue by Country (2019-2024)
12.6.3 MEALA Oncolytic Virus Therapy Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Oncolytic Virus Therapy Market by Type
1.2.1 Global Oncolytic Virus Therapy Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 HSV-based Oncolytic Viruses
1.2.3 Adenoviruses-based Oncolytic Viruses
1.2.4 Vaccinia Virus-based Oncolytic Viruses
1.2.5 Vesicular Stomatitis Virus-based Oncolytic Viruses
1.2.6 Newcastle Disease Virus-based Oncolytic Viruses
1.3 Oncolytic Virus Therapy Market by Application
1.3.1 Global Oncolytic Virus Therapy Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Melanoma
1.3.3 Prostate Cancer
1.3.4 Breast Cancer
1.3.5 Ovarian Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ONCOLYTIC VIRUS THERAPY MARKET DYNAMICS
2.1 Oncolytic Virus Therapy Industry Trends
2.2 Oncolytic Virus Therapy Industry Drivers
2.3 Oncolytic Virus Therapy Industry Opportunities and Challenges
2.4 Oncolytic Virus Therapy Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Oncolytic Virus Therapy Market Perspective (2019-2030)
3.2 Global Oncolytic Virus Therapy Growth Trends by Region
3.2.1 Global Oncolytic Virus Therapy Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Oncolytic Virus Therapy Market Size by Region (2019-2024)
3.2.3 Global Oncolytic Virus Therapy Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Oncolytic Virus Therapy Revenue by Players
4.1.1 Global Oncolytic Virus Therapy Revenue by Players (2019-2024)
4.1.2 Global Oncolytic Virus Therapy Revenue Market Share by Players (2019-2024)
4.1.3 Global Oncolytic Virus Therapy Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Oncolytic Virus Therapy Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Oncolytic Virus Therapy Key Players Headquarters & Area Served
4.4 Global Oncolytic Virus Therapy Players, Product Type & Application
4.5 Global Oncolytic Virus Therapy Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Oncolytic Virus Therapy Market CR5 and HHI
4.6.2 Global Top 5 and 10 Oncolytic Virus Therapy Players Market Share by Revenue in 2023
4.6.3 2023 Oncolytic Virus Therapy Tier 1, Tier 2, and Tier
5 ONCOLYTIC VIRUS THERAPY MARKET SIZE BY TYPE
5.1 Global Oncolytic Virus Therapy Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Oncolytic Virus Therapy Revenue by Type (2019-2030)
5.3 Global Oncolytic Virus Therapy Revenue Market Share by Type (2019-2030)
6 ONCOLYTIC VIRUS THERAPY MARKET SIZE BY APPLICATION
6.1 Global Oncolytic Virus Therapy Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Oncolytic Virus Therapy Revenue by Application (2019-2030)
6.3 Global Oncolytic Virus Therapy Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Comapny Information
7.1.2 Amgen Business Overview
7.1.3 Amgen Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
7.1.5 Amgen Recent Developments
7.2 Oncolytics Biotech
7.2.1 Oncolytics Biotech Comapny Information
7.2.2 Oncolytics Biotech Business Overview
7.2.3 Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
7.2.5 Oncolytics Biotech Recent Developments
7.3 Viralytics
7.3.1 Viralytics Comapny Information
7.3.2 Viralytics Business Overview
7.3.3 Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
7.3.5 Viralytics Recent Developments
7.4 Transgene SA
7.4.1 Transgene SA Comapny Information
7.4.2 Transgene SA Business Overview
7.4.3 Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
7.4.5 Transgene SA Recent Developments
7.5 Oncolys BioPharma
7.5.1 Oncolys BioPharma Comapny Information
7.5.2 Oncolys BioPharma Business Overview
7.5.3 Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
7.5.5 Oncolys BioPharma Recent Developments
7.6 Targovax
7.6.1 Targovax Comapny Information
7.6.2 Targovax Business Overview
7.6.3 Targovax Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
7.6.5 Targovax Recent Developments
7.7 PsiOxus Therapeutics
7.7.1 PsiOxus Therapeutics Comapny Information
7.7.2 PsiOxus Therapeutics Business Overview
7.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
7.7.5 PsiOxus Therapeutics Recent Developments
7.8 SillaJen Biotherapeutics
7.8.1 SillaJen Biotherapeutics Comapny Information
7.8.2 SillaJen Biotherapeutics Business Overview
7.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
7.8.5 SillaJen Biotherapeutics Recent Developments
7.9 Sorrento Therapeutics
7.9.1 Sorrento Therapeutics Comapny Information
7.9.2 Sorrento Therapeutics Business Overview
7.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
7.9.5 Sorrento Therapeutics Recent Developments
7.10 Lokon Pharma
7.10.1 Lokon Pharma Comapny Information
7.10.2 Lokon Pharma Business Overview
7.10.3 Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
7.10.5 Lokon Pharma Recent Developments
7.11 Genelux Corporation
7.11.1 Genelux Corporation Comapny Information
7.11.2 Genelux Corporation Business Overview
7.11.3 Genelux Corporation Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
7.11.5 Genelux Corporation Recent Developments
7.12 Vyriad
7.12.1 Vyriad Comapny Information
7.12.2 Vyriad Business Overview
7.12.3 Vyriad Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
7.12.5 Vyriad Recent Developments
7.13 TILT Biotherapeutics
7.13.1 TILT Biotherapeutics Comapny Information
7.13.2 TILT Biotherapeutics Business Overview
7.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
7.13.5 TILT Biotherapeutics Recent Developments
7.14 Cold Genesys
7.14.1 Cold Genesys Comapny Information
7.14.2 Cold Genesys Business Overview
7.14.3 Cold Genesys Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
7.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
7.14.5 Cold Genesys Recent Developments
8 NORTH AMERICA
8.1 North America Oncolytic Virus Therapy Revenue (2019-2030)
8.2 North America Oncolytic Virus Therapy Revenue by Type (2019-2030)
8.2.1 North America Oncolytic Virus Therapy Revenue by Type (2019-2024)
8.2.2 North America Oncolytic Virus Therapy Revenue by Type (2025-2030)
8.3 North America Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
8.4 North America Oncolytic Virus Therapy Revenue by Application (2019-2030)
8.4.1 North America Oncolytic Virus Therapy Revenue by Application (2019-2024)
8.4.2 North America Oncolytic Virus Therapy Revenue by Application (2025-2030)
8.5 North America Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
8.6 North America Oncolytic Virus Therapy Revenue by Country
8.6.1 North America Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Oncolytic Virus Therapy Revenue by Country (2019-2024)
8.6.3 North America Oncolytic Virus Therapy Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Oncolytic Virus Therapy Revenue (2019-2030)
9.2 Europe Oncolytic Virus Therapy Revenue by Type (2019-2030)
9.2.1 Europe Oncolytic Virus Therapy Revenue by Type (2019-2024)
9.2.2 Europe Oncolytic Virus Therapy Revenue by Type (2025-2030)
9.3 Europe Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
9.4 Europe Oncolytic Virus Therapy Revenue by Application (2019-2030)
9.4.1 Europe Oncolytic Virus Therapy Revenue by Application (2019-2024)
9.4.2 Europe Oncolytic Virus Therapy Revenue by Application (2025-2030)
9.5 Europe Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
9.6 Europe Oncolytic Virus Therapy Revenue by Country
9.6.1 Europe Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Oncolytic Virus Therapy Revenue by Country (2019-2024)
9.6.3 Europe Oncolytic Virus Therapy Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Oncolytic Virus Therapy Revenue (2019-2030)
10.2 China Oncolytic Virus Therapy Revenue by Type (2019-2030)
10.2.1 China Oncolytic Virus Therapy Revenue by Type (2019-2024)
10.2.2 China Oncolytic Virus Therapy Revenue by Type (2025-2030)
10.3 China Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
10.4 China Oncolytic Virus Therapy Revenue by Application (2019-2030)
10.4.1 China Oncolytic Virus Therapy Revenue by Application (2019-2024)
10.4.2 China Oncolytic Virus Therapy Revenue by Application (2025-2030)
10.5 China Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Oncolytic Virus Therapy Revenue (2019-2030)
11.2 Asia Oncolytic Virus Therapy Revenue by Type (2019-2030)
11.2.1 Asia Oncolytic Virus Therapy Revenue by Type (2019-2024)
11.2.2 Asia Oncolytic Virus Therapy Revenue by Type (2025-2030)
11.3 Asia Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
11.4 Asia Oncolytic Virus Therapy Revenue by Application (2019-2030)
11.4.1 Asia Oncolytic Virus Therapy Revenue by Application (2019-2024)
11.4.2 Asia Oncolytic Virus Therapy Revenue by Application (2025-2030)
11.5 Asia Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
11.6 Asia Oncolytic Virus Therapy Revenue by Country
11.6.1 Asia Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Oncolytic Virus Therapy Revenue by Country (2019-2024)
11.6.3 Asia Oncolytic Virus Therapy Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Oncolytic Virus Therapy Revenue (2019-2030)
12.2 MEALA Oncolytic Virus Therapy Revenue by Type (2019-2030)
12.2.1 MEALA Oncolytic Virus Therapy Revenue by Type (2019-2024)
12.2.2 MEALA Oncolytic Virus Therapy Revenue by Type (2025-2030)
12.3 MEALA Oncolytic Virus Therapy Revenue Share by Type (2019-2030)
12.4 MEALA Oncolytic Virus Therapy Revenue by Application (2019-2030)
12.4.1 MEALA Oncolytic Virus Therapy Revenue by Application (2019-2024)
12.4.2 MEALA Oncolytic Virus Therapy Revenue by Application (2025-2030)
12.5 MEALA Oncolytic Virus Therapy Revenue Share by Application (2019-2030)
12.6 MEALA Oncolytic Virus Therapy Revenue by Country
12.6.1 MEALA Oncolytic Virus Therapy Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Oncolytic Virus Therapy Revenue by Country (2019-2024)
12.6.3 MEALA Oncolytic Virus Therapy Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
